Work

Predictors of Cirrhosis and Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis: An Academic Center Experience

Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background and goals: Outcomes of patients with primary sclerosing cholangitis (PSC) in Central Missouri are unknown. The University of Missouri-Columbia services 600,000 individuals in Central Missouri. Our aims were to a) examine the outcomes of PSC patients receiving care at our academic institution, and b) identify predictors of PSC-related serious adverse events. Methods: A retrospective study of patients with PSC in a non-transplant center. Primary outcome was development of ≥ 1 of PSC-related serious adverse event: 1) progression to cirrhosis, or 2) development of cholangiocarcinoma. Results: From year 2000 to 2018, 42 patients fulfilled the criteria for the diagnosis of PSC. 55% were male, 79% had associated inflammatory bowel disease (IBD). The median follow-up from time of diagnosis of PSC until last follow up or death was 5.5 years. Fifty-seven percent of patients developed ≥1 PSC-related adverse event; 36% (8/22) of those who progressed to decompensation underwent liver transplantation. The median time from diagnosis of PSC until progression to decompensation was 6.3 years. The median time from decompensation to transplantation was 10.8 years. Twelve percent developed ≥1 cancer (cholangiocarcinoma=2; gallbladder cancer=2; colon cancer =1; and hepatocellular carcinoma =1). The overall mortality was 9.5%. The median time from PSC diagnosis until death was 10.2 years. Cox hazards regression analysis showed only age (HR=1.05; p=0.028; 95% CI, 1.01-1.11) and serum bilirubin (HR= 1.55; p=0.033; 95% CI, 1.03-2.28) at the time of PSC diagnosis. Conclusion: Age and bilirubin are important predictors of PSC-related outcomes.
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: green
OpenAlex ID: W7128364243
Cites:
Cited by:
Related to: 10